Head & Neck Cancers

FDA Approval Sought for Pralsetinib in Advanced RET+ Thyroid Cancers

July 2nd 2020, 12:12am

A new drug application has been submitted to the FDA for pralsetinib (BLU-667) for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion–positive thyroid cancers.

Marvels in Medicine: Vokes’s Venture to Bring Combined Modality Care to Patients With Cancer

June 22nd 2020, 8:05pm

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

FDA Expands Gardasil 9 Indication for Prevention of Select HPV-Related Head and Neck Cancers

June 15th 2020, 1:19pm

The FDA has approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus types 16, 18, 31, 33, 45, 52, and 58.

FDA Approves Selpercatinib for RET+ NSCLC and Thyroid Cancers

May 9th 2020, 2:05am

The FDA has approved selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion–positive non–small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion–positive thyroid cancer.

Dr. Saba on Unique Set of Challenges Caused By COVID-19 in Head and Neck Cancer

May 7th 2020, 6:25pm

Nabil F. Saba, MD, FACP, discusses how the COVID-19 pandemic has impacted treatment in head and neck cancer and the health care system at large.

Investigators Seek to Supplant Oropharyngeal SOC With Proton Therapy

April 30th 2020, 6:29pm

Hoping to minimize the off-target effects associated with radiation in patients with oropharyngeal cancer, investigators are testing the hypothesis that intensitymodulated proton therapy can deliver doses as effectively as the current standard of care with less damage to surrounding tissue.

Dr. Ferris on Ongoing Research With STING Agonists/Checkpoint Inhibitors in Head and Neck Cancer

April 30th 2020, 2:02am

Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.

Dr. Ferris on a Trial Testing ADU-S100/MIW815/Pembrolizumab in Head and Neck Cancer

April 28th 2020, 10:00pm

Robert L. Ferris, MD, PhD, director of University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Hillman Professor of Oncology, associate vice chancellor for cancer research, professor of otolaryngology, immunology, and radiation oncology, co-director, Tumor Microenvironment Center, UPMC Hillman Cancer Center, discusses a clinical trial testing ADU-S100/MIW815 plus pembrolizumab (Keytruda) in patients with head and neck cancer.

Dr. Burtness on the Effectiveness of Immunotherapy in Head and Neck Cancers

March 31st 2020, 2:17am

Barbara Burtness, MD, discusses the effectiveness of immunotherapy in patients with platinum-refractory head and neck cancers.

Frontline Avelumab Falls Short in Phase III Head and Neck Cancer Study

March 13th 2020, 8:57pm

The phase III JAVELIN Head and Neck 100 trial has been terminated after an interim analysis showed that the addition of avelumab to standard-of-care chemoradiotherapy was unlikely to lead to a statistically significant improvement in progression-free survival in patients with untreated locally advanced squamous cell carcinoma of the head and neck.